2F-Viminol

2F-Viminol
Legal status
Legal status
Identifiers
IUPAC name
  • 2-[di(butan-2-yl)amino]-1-[1-[(2-fluorophenyl)methyl]pyrrol-2-yl]ethanol
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC21H31FN2O
Molar mass346.490 g·mol−1
3D model (JSmol)
SMILES
  • FC1=C(CN2C=CC=C2C(O)CN(C(CC)C)C(C)CC)C=CC=C1
InChI
  • InChI=1S/C21H31FN2O/c1-5-16(3)24(17(4)6-2)15-21(25)20-12-9-13-23(20)14-18-10-7-8-11-19(18)22/h7-13,16-17,21,25H,5-6,14-15H2,1-4H3
  • Key:FXQMNNHPOYWWKI-UHFFFAOYSA-N

2F-Viminol is a pyrrole derived opioid analgesic drug, which was originally developed by a team at the drug company Zambon in the 1960s. It is around twice as potent as the parent compound viminol, though unlike viminol, 2F-viminol has never passed clinical trials or been approved for medical use. 2F-Viminol has been sold as a designer drug, first being identified in Sweden in 2019.[1] It is one of a number of structurally atypical opioid agonists to have appeared on the designer drug grey-market since broad controls over fentanyl analogues were introduced in China in 2015.[2] It was made illegal in Sweden in August 2019 and in Latvia in November 2019.[3]

See also

References

  1. ↑ "Ordinance banning certain products that are harmful to health". Swedish Code of Statutes. 4 July 2019. This Ordinance enters into force on 6 August 2019
  2. ↑ Bao Y, Meng S, Shi J, Lu L (July 2019). "Control of fentanyl-related substances in China". The Lancet. Psychiatry. 6 (7): e15. doi:10.1016/S2215-0366(19)30218-4. PMID 31230685.
  3. ↑ "SPKC nosaka aizliegumu vielām 2F-viminol, furanyl UF – 17 un to saturošiem izstrādājumiem" [SPKC bans 2F-viminol, furanyl UF-17 and products containing them]. Slimību profilakses un kontroles centrs (Center for Disease Prevention and Control) (in Latvian). 6 November 2019.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.